In a preceding investigation, we demonstrated that atorvastatin and rosuvastatin selectively suppress PAR-2 expression in LPS-stimulated HT-29 and Caco-2 colorectal cancer cells while leaving PAR-1 expression unaffected [44], which we have also validated in this investigation (Figure 2 and Figure 3). Here, F2RL1 is linked to colorectal cancer.